Filing Details
- Accession Number:
- 0000899243-19-013104
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-05-10 18:00:18
- Reporting Period:
- 2019-05-08
- Accepted Time:
- 2019-05-10 18:00:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1103021 | Biodelivery Sciences International Inc | BDSI | Pharmaceutical Preparations (2834) | 352089858 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1739458 | Herm Cukier | C/O Biodelivery Sciences Intl, Inc. 4131 Parklake Ave. Suite 225 Raleigh NC 27612 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-05-08 | 66,666 | $0.00 | 66,666 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-05-08 | 29,425 | $5.07 | 37,421 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-05-09 | 860 | $4.92 | 36,381 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Acquisiton | 2019-05-08 | 66,666 | $0.00 | 66,666 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 133,334 | 2021-05-08 | No | 4 | M | Direct |
Footnotes
- The shares of common stock were acquired by the Reporting Person as a result of the vesting of 66,666 Performance Restricted Stock Units ("PRSUs") granted to the Reporting Person on May 2, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended , subject to certain performance measures. The remainder of the PRSUs under this grant will vest: i) one-half after the first open window upon the filing of the Company's Annual Report in March 2020 subject to certain performance measures and ii) the remaining half after the first open window upon the filing of the Company's Annual Report in March 2021 subject to certain performance measures. The PRSUs convert into common stock on a one-for-one basis.
- The shares of Common Stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of PRSUs.
- On May 8, 2019, the Reporting Person sold an aggregate of 29,425 shares of the Common Stock at a weighted average price of $5.07 per share. The highest sale price for the Common Stock was $5.19 per share and the lowest sale price was $4.99 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in these footnotes.
Billionaire Hedge Funds
